基于Meta分析探讨安宫降压丸治疗初发难治性高血压病的有效性和安全性评价

Evaluating the effectiveness and safety of Angong Jiangya Wan on newly-onset refractory hypertension based on meta-analysis

目的:通过Meta分析探讨安宫降压丸联合常规西药治疗初发难治性高血压病的疗效。方法:搜集安宫降压丸联用常规降压药治疗初发难治性高血压病的随机对照试验文献资料进行Meta分析。计算机检索Cochrane临床对照试验中心注册库、PubMed、Embase、中国生物医学文献、中国知网、维普中文科技期刊数据库、万方数据库相关期刊,检索时间均从建库至2021年4月30日,同时检查参考文献列表及相关综述;由两名评价员独立提取资料,根据Cochrane 4.2.2进行文献质量评价,采用Cochrane RevMan 5.3软件进行异质性检验、Meta分析、发表偏倚分析相关统计数据。结果:共纳入9篇文献,纳入650例患者,所有研究地点均在中国,均为中文发表。Meta分析表明,试验组降压的有效率明显优于对照组,降低患者24 h动态血压值的疗效优于对照组。结论:结果表明,在常规降压方案基础上联用安宫降压丸可以进一步改善难治性高血压病患者的临床疗效且具有良好的安全性,但仍需更多高质量的临床研究加以验证。

Objective:To explore the efficacy of Angong Jiangya Wan(安宫降压丸)plus conventional western medicine on newlyonset refractory hypertension through meta-analysis.Methods:The literature data of randomized controlled trials of Angong Jiangya Wan plus conventional antihypertensive drugs on newly diagnosed and refractory hypertension were collected for meta-analysis.The literature was searched in Cochrane Clinical Controlled Trials Center Registry,PubMed,Embase,CBM,CNKI,VIP,Wanfang Database related journals,the search time was from the establishment of the database to April 30,2021,and the reference documents list and related reviews were checked at the same time;two reviewers independently extracted data,evaluated literature quality according to Cochrane Manual 4.2.2,and used Cochrane RevMan 5.3 software for heterogeneity test,meta-analysis,and publication bias analysis of related statistical data.Results:A total of 9 articles were included,with 650 cases.All research sites were in China and all were published in Chinese.Metaanalysis shows that the effective rate of blood pressure reduction in the test group was significantly better than the control group,the therapeutic effect in the test group on reducing the patient’s 24 h ambulatory blood pressure was better than the control group.Conclusion:The results show that the Angong Jiangya Wan plus conventional antihypertensive programs can further improve the clinical efficacy of patients with refractory hypertension,and has good safety.However,more high-quality clinical studies were still needed for verification.